SGX Market Strategist, Equity & Fixed Income, Singapore Exchange Ltd (SGX)

Geoff Howie

SGX Market Strategist, Equity & Fixed Income

Asia’s leading multi-asset exchange

Singapore Exchange Ltd (SGX)

Singapore Exchange is Asia’s leading and trusted market infrastructure, facilitating the exchange of capital and ideas to create value for people, businesses and economies. As a multi-asset exchange operating equity, fixed income and derivatives markets to the highest regulatory standards, SGX is a vertically integrated business that provides listing, trading, clearing, settlement, depository and data services.

With about 40% of listed companies and over 80% of listed bonds originating outside of Singapore as well as established linkages across the region and in Europe, SGX is Asia’s most international and connected exchange. Offering a full suite of derivatives products across Asian equity indices, commodities and currencies, SGX is the world’s most liquid international market for the benchmark equity indices of China, India, Japan and ASEAN.

As Asia’s pioneering central counterparty, SGX is globally recognised for its risk management and clearing capabilities, and was one of the first globally to adopt the Principles for Financial Market Infrastructure.

Headquartered in AAA-rated Singapore, SGX has over 800 employees including offices in Beijing, Chicago, Hong Kong, London, New York, Mumbai, San Francisco, Shanghai and Tokyo.

<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">



APAC IPOs & Placements

Zhen Zhou, Toh

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Event-Driven

Thomson Medical Group Limited / Event-Driven

<p><a href="https://www.smartkarma.com/entities/8495" target="_blank" data-smartkarma-citation="entities:8495:1">Rowsley Ltd (ROWS SP)</a> announced that earlier in July that it will be buying Sasteria, the company that holds Thomson Medical. On 18th December, the company released a corporate presentation as the company entered into a sale and purchase agreement (S&amp;P agreement).</p><p>Post announcement, Rowsley's share price rallied about 20% from the previous close, but, we think that the market has been showing a tad too much of irrational exuberance.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/040/773/original/One-Year-Price-Chart-of-Rowsley-SGD-Last-Price-Volume-000-_chartbuilder.png?1513667338" class="editor-image img-responsive" data-smartkarma-image-id="40773"></figure><h2>Details of the acquisition<br><br>
</h2><ul><li>Rowsley will be buying Sasteria for…</li></ul>

Rowsley Ltd (ROWS SP) announced that earlier in July that it will be buying Sasteria, the company that holds Thomson Medical. On 18th December, the company released a corporate presentation as the company entered into a sale and purchase agreement (S&amp;P agreement).Post announcement, Rowsley's share price rallied about 20% from the previous close, but, we think that the market has been showing a tad too much of irrational exuberance.Details of the acquisition  
Rowsley will be buying Sasteria for…

Signs of Irrational Exuberance as Rowsley Transforms into Thomson Medical

Clearbridge Health – A Play on Asia’s Precision Medicine Market

Annual Sector Rotations that Beat the STI in 2017 YTD

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Bottom-Up

<p><a href="https://www.smartkarma.com/entities/879" target="_blank" data-smartkarma-citation="entities:879:1">Raffles Medical Group Ltd (RFMD SP)</a> 's Q3 2017 results featured practically zero growth in revenue and profits. Management's guidance for start-up losses at new hospitals in China in 2018 and 2019 make for a sobering outlook. Forward estimates have become much more realistic. The shares need to go lower to offer any real value.  </p><h2>Results Highlights:</h2><ul>
<li>Revenue: +0.3% on a continued drop in international patients</li>
<li>Operating income: down 0.9% with very tight cost containment in most expense categories.</li>
<li>…</li>
</ul>

Raffles Medical Group Ltd (RFMD SP) 's Q3 2017 results featured practically zero growth in revenue and profits. Management's guidance for start-up losses at new hospitals in China in 2018 and 2019 make for a sobering outlook. Forward estimates have become much more realistic. The shares need to go lower to offer any real value.  Results Highlights:
Revenue: +0.3% on a continued drop in international patients
Operating income: down 0.9% with very tight cost containment in most expense categories.
…


Singapore

Raffles Medical Group Limited is a health care provider.  The Company operates medical clinics, imaging centers, and medical laboratories.  Raffles provides general and specialized medical, medical evacuation, medical advisory, and dental treatment services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Raffles Medical Group (RFMD SP)

Sector Leaders that Beat the STI in 2017

Singapore Exchange Ltd (SGX)

Signs of Irrational Exuberance as Rowsley Transforms into Thomson Medical

Rowsley Ltd (ROWS SP) announced that earlier in July that it will be buying Sasteria, the company that holds Thomson Medical. On 18th December, the...

Zhen Zhou, Toh

Clearbridge Health – A Play on Asia’s Precision Medicine Market

Singapore Exchange Ltd (SGX)

Annual Sector Rotations that Beat the STI in 2017 YTD

Singapore Exchange Ltd (SGX)

Q3: Reality Starting to Sink In

Raffles Medical Group Ltd (RFMD SP) 's Q3 2017 results featured practically zero growth in revenue and profits. Management's guidance for start-up...

Kemp Dolliver, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)